Pharmacokinetics and Pharmacodynamics Practice Questions

Q: G-protein coupled receptor that does not act through opening of potassium channels is:

Angiotensin 1 receptor. ***Angiotensin 1 receptor*** - The **angiotensin 1 receptor (AT1R)** is a **Gq-coupled receptor** that primarily activates the **phospholipase C (PLC)** pathway, leading to increased intracellular **calcium** and **IP3/DAG** signaling. - Its activation mediates vasoconstriction, aldosterone release, and cardiac hypertrophy, none of which involve direct opening of potassium channels. *Dopamine D2 receptor* - **Dopamine D2 receptors** are **Gi/o-coupled receptors** that inhibit adenylyl cyclase and **open potassium channels**, leading to **hyperpolarization** and reduced neuronal excitability. - This action contributes to its **antipsychotic** and **motor control** effects. *Muscarinic M2 receptor* - **Muscarinic M2 receptors** are **Gi/o-coupled receptors** found in the heart that cause **bradycardia** by activating **acetylcholine-gated inwardly rectifying potassium (GIRK) channels**, leading to hyperpolarization. - They also inhibit adenylyl cyclase, reducing cAMP levels and decreasing heart rate and contractility. *Serotonin 5 HT 1 receptor* - **Serotonin 5-HT1 receptors** (e.g., 5-HT1A) are **Gi/o-coupled receptors** that, upon activation, **increase potassium conductance** (hyperpolarization) and inhibit adenylyl cyclase. - This leads to a reduction in neuronal firing and is implicated in the anxiolytic and antidepressant effects of these receptors.

Q: All are true for cytochrome P450 enzymes EXCEPT:

Synthesize amino acids. ***Synthesize amino acids*** - Cytochrome P450 enzymes are primarily involved in the **metabolism of xenobiotics** and endogenous compounds, not in the synthesis of amino acids. - **Amino acid synthesis** occurs through different metabolic pathways involving various enzymes distinct from the cytochrome P450 system. *Involved in drug metabolism* - Cytochrome P450 enzymes are a major group of enzymes crucial for the **biotransformation of numerous drugs** and other foreign compounds. - They typically catalyze **oxidation reactions**, preparing drugs for excretion. *Present mainly in the liver* - While present in many tissues, the **highest concentration and diversity** of cytochrome P450 enzymes are found in the **liver**, which is the primary site of drug metabolism. - They are also found in the gastrointestinal tract, kidney, lung, and brain, but to a lesser extent. *Part of Phase I metabolism* - Cytochrome P450 enzymes are the **principal enzymes responsible for Phase I reactions** in drug metabolism. - **Phase I metabolism** generally involves reduction, oxidation, or hydrolysis reactions to introduce polar groups to the drug molecule.

Q: What is the primary role of Cytochrome P450 enzymes in the liver?

Oxidation of drugs. ***Oxidation of drugs*** - **Cytochrome P450 enzymes** are a superfamily of monooxygenases that primarily catalyze the **oxidation of various endogenous and exogenous substrates**, including drugs [1, 2]. - This oxidative metabolism is a key step in detoxification and elimination of foreign compounds from the body [1]. *Lipid transport* - **Lipid transport** is primarily facilitated by **lipoproteins** and specific **transport proteins** in the blood and within cells. - While P450 enzymes can metabolize some lipids, their primary role is not in lipid transport [2]. *Carbohydrate synthesis* - **Carbohydrate synthesis**, or **gluconeogenesis**, is mainly carried out by enzymes such as **pyruvate carboxylase** and **fructose-1,6-bisphosphatase**. - Cytochrome P450 enzymes do not play a direct role in the synthesis of carbohydrates. *Protein degradation* - **Protein degradation** is largely mediated by the **ubiquitin-proteasome system** and **lysosomal pathways**. - Cytochrome P450 enzymes are not directly involved in breaking down proteins into smaller peptides or amino acids.

Q: What are the purposes of using epinephrine in conjunction with local anesthetics?

All of the options. ***All of the options*** - Epinephrine is a **vasoconstrictor** that produces all three of the listed benefits when combined with local anesthetics. - The **vasoconstrictive effect** reduces blood flow at the injection site, which simultaneously achieves multiple therapeutic purposes. - All three mechanisms work together through a single pharmacological action: **local vasoconstriction**. **1. Prolongs the duration of anesthesia:** - Vasoconstriction reduces blood flow to the area, delaying the washout of the local anesthetic from the nerve site. - This maintains a higher local concentration of anesthetic for a longer period, extending the duration of nerve block. - Duration can be increased by 50-100% depending on the site and anesthetic used. **2. Decreases systemic absorption:** - By constricting local blood vessels, epinephrine slows the rate at which the local anesthetic enters the systemic circulation. - This reduces peak plasma concentrations, **lowering the risk of systemic toxicity** (CNS and cardiac effects). - Allows use of higher total doses of local anesthetic when needed. **3. Reduces bleeding:** - The vasoconstrictive effect directly narrows small blood vessels in the surgical field. - This **reduces capillary bleeding**, improving surgical visibility and decreasing blood loss during procedures. - Particularly useful in highly vascular areas like the oral cavity and scalp.

Q: A drug has a therapeutic index of 5 and an ED50 of 2 mg. What is the LD50 of the drug?

10 mg. ***10 mg*** - The **therapeutic index (TI)** is calculated as **LD50 / ED50**. - Given a TI of 5 and an ED50 of 2 mg, the LD50 = TI × ED50 = 5 × 2 mg = **10 mg**. - This is the correct application of the therapeutic index formula. *15 mg* - This value would imply a therapeutic index of 7.5 (15 mg / 2 mg), which is incorrect based on the given information. - Does not align with the definition and calculation of the therapeutic index. *8 mg* - This value would result in a therapeutic index of 4 (8 mg / 2 mg), not the given TI of 5. - Represents an incorrect application of the therapeutic index formula. *12 mg* - This value would yield a therapeutic index of 6 (12 mg / 2 mg), differing from the provided TI of 5. - Does not correctly reflect the relationship between ED50, LD50, and the therapeutic index.

Q: A new drug shows that its therapeutic dose-response curve and toxic dose-response curve are closely positioned on the dose axis. What can be inferred about its therapeutic index and safety profile?

Lower therapeutic index, increased risk of toxicity. ***Lower therapeutic index, increased risk of toxicity*** - When the **therapeutic and toxic dose-response curves are closely positioned**, there is a narrow margin between the dose that produces therapeutic effects and the dose that causes toxicity - This narrow separation indicates a **low therapeutic index (TI = TD50/ED50)**, where TD50 (toxic dose) and ED50 (effective dose) are close in value - Clinically, this means **increased risk of toxicity** as small dose increases or patient variability can easily shift from therapeutic to toxic range - Examples include drugs like **digoxin, warfarin, and aminoglycosides** which require careful monitoring *Higher therapeutic index, increased safety* - This would be true if the toxic dose-response curve was **far separated** from the therapeutic curve on the dose axis - Close positioning of curves indicates **low, not high** therapeutic index - Higher therapeutic index drugs have a wide safety margin (e.g., penicillins, most NSAIDs) *Lower therapeutic index, unchanged efficacy* - While **lower therapeutic index** is correct, "unchanged efficacy" is not a relevant inference from curve positioning - **Efficacy** refers to the maximal effect (Emax), represented by the plateau height of the dose-response curve, not its position on the dose axis - Therapeutic index and efficacy are independent parameters *Higher therapeutic index, unchanged potency* - Close positioning of therapeutic and toxic curves indicates **lower, not higher** therapeutic index - **Potency** (dose required for effect, reflected by ED50 position) is independent of therapeutic index - A drug can be highly potent but have a low therapeutic index if toxic effects occur at doses close to therapeutic doses

Q: A patient requires immediate relief from an acute asthma attack. Which route of administration would provide the fastest effect?

Inhalation. ***Inhalation*** - **Inhalation** delivers medication directly to the **airways**, the site of action for asthma, allowing for rapid absorption and immediate local bronchodilation. - This route provides **targeted drug delivery** to bronchial smooth muscle, achieving therapeutic effect within **1-5 minutes** for acute asthma relief. - Bypasses first-pass metabolism and requires **lower doses** due to direct delivery to the target organ. - **First-line treatment** for acute asthma attacks in clinical practice. *Oral* - **Oral administration** involves absorption from the gastrointestinal tract, which is a slower process, with onset typically taking **30-60 minutes**. - Medications taken orally undergo **first-pass metabolism** in the liver, reducing bioavailability and delaying therapeutic effect. - Not suitable for **acute** asthma management due to delayed onset. *Subcutaneous* - **Subcutaneous injections** are absorbed more slowly than intravenous or inhaled routes, with onset in **15-30 minutes**. - The drug must diffuse from subcutaneous tissue into the bloodstream before reaching the lungs. - May be used for severe asthma (e.g., subcutaneous epinephrine) but **not preferred** over inhalation for typical acute attacks. *Intravenous* - While **intravenous administration** provides immediate systemic delivery with rapid onset, it is **not the first choice** for acute asthma. - Reserved for **severe, life-threatening asthma** unresponsive to inhaled therapy. - Requires IV access, medical supervision, and carries higher risk of systemic side effects. - For acute asthma relief, **inhaled bronchodilators act faster at the target site** despite IV having faster systemic absorption.

Q: A patient with a severe infection is given a drug with a half-life of 8 hours. How long will it take for the drug's concentration to decrease to 25% of its original value?

16 hours. ***16 hours (Correct)*** - After one **half-life** (8 hours), the drug concentration will be 50% of the original value. - After two half-lives (8 hours + 8 hours = **16 hours**), the drug concentration will be 25% of the original value (50% of 50%). - This follows the exponential decay formula: remaining concentration = (1/2)^n, where n is the number of half-lives. *8 hours (Incorrect)* - This represents only one half-life, at which point the drug's concentration would be reduced to 50%, not 25%, of its original value. - The question asks for the time to reach 25% concentration, which requires an additional half-life. *24 hours (Incorrect)* - This duration represents three half-lives (8 hours × 3). - After three half-lives, the drug concentration would be 12.5% of its original value (50% → 25% → 12.5%). *32 hours (Incorrect)* - This duration represents four half-lives (8 hours × 4). - After four half-lives, the drug concentration would be 6.25% of its original value (12.5% → 6.25%).

Question 1

G-protein coupled receptor that does not act through opening of potassium channels is:

Accepted Answer

Angiotensin 1 receptor

Answer

Dopamine D2 receptor

Answer

Muscarinic M2 receptor

Answer

Serotonin 5 HT 1 receptor

Question 2

All are true for cytochrome P450 enzymes EXCEPT:

Accepted Answer

Synthesize amino acids

Answer

Involved in drug metabolism

Answer

Present mainly in the liver

Answer

Part of Phase I metabolism

Question 3

What is the primary role of Cytochrome P450 enzymes in the liver?

Accepted Answer

Oxidation of drugs

Answer

Lipid transport

Answer

Carbohydrate synthesis

Answer

Protein degradation

Question 4

Which of the following statements is true regarding zero-order kinetics?

Accepted Answer

Follows a constant rate of elimination regardless of concentration.

Answer

Commonly seen in therapeutic doses of most drugs.

Answer

Rate of elimination depends on drug concentration.

Answer

Occurs only at subtherapeutic doses of drugs.

Question 5

What are the purposes of using epinephrine in conjunction with local anesthetics?

Accepted Answer

All of the options

Answer

To prolong the duration of anesthesia

Answer

To decrease systemic absorption

Answer

To reduce bleeding

Question 6

A drug has a therapeutic index of 5 and an ED50 of 2 mg. What is the LD50 of the drug?

Accepted Answer

10 mg

Answer

15 mg

Answer

8 mg

Answer

12 mg

Question 7

A new drug shows that its therapeutic dose-response curve and toxic dose-response curve are closely positioned on the dose axis. What can be inferred about its therapeutic index and safety profile?

Accepted Answer

Lower therapeutic index, increased risk of toxicity

Answer

Higher therapeutic index, increased safety

Answer

Lower therapeutic index, unchanged efficacy

Answer

Higher therapeutic index, unchanged potency

Question 8

When comparing oral and intravenous routes of administration, which statement best describes the difference in bioavailability?

Accepted Answer

Oral has lower bioavailability due to first-pass metabolism.

Answer

Oral has lower bioavailability due to prolonged absorption.

Answer

Intravenous has higher bioavailability due to rapid distribution.

Answer

Intravenous has higher bioavailability due to increased absorption.

Question 9

A patient requires immediate relief from an acute asthma attack. Which route of administration would provide the fastest effect?

Accepted Answer

Inhalation

Answer

Oral

Answer

Subcutaneous

Answer

Intravenous

Question 10

A patient with a severe infection is given a drug with a half-life of 8 hours. How long will it take for the drug's concentration to decrease to 25% of its original value?

Accepted Answer

16 hours

Answer

8 hours

Answer

24 hours

Answer

32 hours

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?